| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.96 M USD | -12.62 M USD | -6.68 M USD | -6.46 M USD | -6.55 M USD | -2.56 M USD | -609000 USD | -635000 USD |
| Depreciation & Amortization | 15000 USD | 16000 USD | 15000 USD | 15000 USD | 7000 USD | — | 1000 USD | — |
| Stock-Based Compensation | 447000 USD | 310000 USD | 804000 USD | 1.39 M USD | 812000 USD | 38000 USD | 89000 USD | — |
| Capital Expenditures | 2000 USD | 13000 USD | 9000 USD | 6000 USD | 50000 USD | 10000 USD | 0 USD | — |
| Cash Flow from Investing | -982000 USD | -13000 USD | 5.99 M USD | -6.01 M USD | -50000 USD | -10000 USD | 0 USD | — |
| Cash Flow from Financing | 3.82 M USD | 8.86 M USD | 4.62 M USD | 0 USD | 7.48 M USD | 17.31 M USD | 1.51 M USD | 488000 USD |
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — |
| Free Cash Flow | -3.96 M USD | -12.63 M USD | -6.69 M USD | -6.46 M USD | -6.60 M USD | -2.57 M USD | -609000 USD | — |
PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for surgical and post-operative pain management. Its core product, PRF-110, is designed as an oil-based, viscous solution applied directly into the surgical wound bed before closure to provide localized and extended analgesia. The company’s work centers on improving drug delivery in areas where sustained pain control and targeted treatment are important, particularly in hospital-based surgical settings. PainReform Ltd. operates in the healthcare and drug development sectors, where it contributes to the development of specialized treatment options built around existing active ingredients and delivery technologies. Headquartered in Israel, the company remains focused on advancing products intended for post-operative care and other clinical applications.